Ongoing clinical research at UNC could lead to a first-of-its-kind enzyme replacement therapy for Hunter syndrome, an ...

Denali Therapeutics Inc. DNLI recently outlined its roadmap for 2026 across its portfolio of investigational therapies for ...

Preparing for FDA approval and commercial launch of tividenofusp alfa, Denali’s TransportVehicle™ (TV)-enabled investigational therapy for Hunter ...

As Kristin McKay and her family celebrate another holiday season with their beloved son Charlie, they do so with the ...

Denali Therapeutics (DNLI) drew fresh interest after publishing Phase 1/2 trial results for its Hunter syndrome therapy, ...

The Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for tividenofusp alfa for the treatment of Hunter syndrome, also known as ...

Denali Therapeutics announced that results from its open-label Phase 1/2 trial of tividenofusp alfa for Hunter syndrome were published in the January 1, 2026 issue of The New England Journal of ...

Tividenofusp alfa treatment showed reduction and normalization in key disease biomarkers, stabilization or improvement in clinical endpoints ...

Fifteen-year-old Dominic Henriquez from Prosper, Texas, is bringing hope to boys like him who live with Hunter syndrome, a rare genetic disorder that primarily affects males. Dominic’s journey began ...

The devastating consequences of mucopolysaccharidosis II (MPS II), also called Hunter syndrome, may soon become preventable ...

Emily Lieber is the kind of teacher you remember: Patient and fun, energetic and creative. Many of the kindergartners and first graders she has taught at Meredith Elementary School in South ...